News

American Association of Individual Investors1d
Why BioCryst Pharmaceuticals, Inc.’s (BCRX) Stock Is Down 5.30%
BioCryst Pharmaceuticals, Inc.’s BCRX share price has dipped by 5.30%, which has investors questioning if this is right time ...
Fintel on MSN7d
Cantor Fitzgerald Initiates Coverage of BioCryst Pharmaceuticals (BCRX) with Overweight Recommendation
Fintel reports that on April 29, 2025, Cantor Fitzgerald initiated coverage of BioCryst Pharmaceuticals (NasdaqGS:BCRX) with ...
American Association of Individual Investors1d
Why BioCryst Pharmaceuticals, Inc.’s (BCRX) Stock Is Up 15.73%
BioCryst Pharmaceuticals, Inc.’s BCRX share price has surged by 15.73%, which has investors questioning if this is right time to sell.
Seeking Alpha4d
BCRX BioCryst Pharmaceuticals, Inc.
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO ...
ETF Daily News1mon
Vanguard Group Inc. Has $164.62 Million Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO ...